Published in

Elsevier, Journal of Molecular and Cellular Cardiology, (59), p. 67-75, 2013

DOI: 10.1016/j.yjmcc.2013.02.001

Links

Tools

Export citation

Search in Google Scholar

Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia–reperfusion-induced ventricular arrhythmias

Journal article published in 2013 by Fu Siong Ng ORCID, Iqbal T. Shadi, Nicholas S. Peters, Alexander R. Lyon
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

BACKGROUND: Heart rates during ischaemia and reperfusion are possible determinants of reperfusion arrhythmias. We used ivabradine, a selective I(f) current inhibitor, to assess the effects of heart rate reduction (HRR) during ischaemia-reperfusion on reperfusion ventricular arrhythmias and assessed potential anti-arrhythmic mechanisms by optical mapping. METHODS: Five groups of rat hearts were subjected to regional ischaemia by left anterior descending artery occlusion for 8minutes followed by 10minutes reperfusion: (1) Control n=10; (2) 1μM ivabradine perfusion n=10; (3) 1μM ivabradine+5Hz atrial pacing throughout ischaemia-reperfusion n=5; (4) 1μM ivabradine+5Hz pacing only at reperfusion; (5) 100μM ivabradine was used as a 1mL bolus upon reperfusion. For optical mapping, 10 hearts (ivabradine n=5; 5Hz pacing n=5) were subjected to global ischaemia whilst transmembrane voltage transients were recorded. Epicardial activation was mapped, and the rate of development of ischaemia-induced electrophysiological changes was assessed. RESULTS: HRR observed in the ivabradine group during both ischaemia (195±11bpm vs. control 272±14bpm, p<0.05) and at reperfusion (168±13bpm vs. 276±14bpm, p<0.05) was associated with reduced reperfusion ventricular fibrillation (VF) incidence (20% vs. 90%, p<0.05). Pacing throughout ischaemia-reperfusion abolished the protective effects of ivabradine (100% VF), whereas pacing at reperfusion only partially attenuated this effect (40% VF). Ivabradine, given as a bolus at reperfusion, did not significantly affect VF incidence (80% VF). Optical mapping experiments showed a delay to ischaemia-induced conduction slowing (Time to 50% conduction slowing: 10.2±1.3 mins vs. 5.1±0.7 mins, p<0.05) and to loss of electrical excitability in ivabradine-perfused hearts (27.7±4.3 mins vs. 14.5±0.6 mins, p<0.05). CONCLUSIONS: Ivabradine administered throughout ischaemia and reperfusion reduced reperfusion VF incidence through HRR. Heart rate during ischaemia is a major determinant of reperfusion arrhythmias. Heart rate at reperfusion alone was not a determinant of reperfusion VF, as neither a bolus of ivabradine nor pacing immediately prior to reperfusion significantly altered reperfusion VF incidence. This anti-arrhythmic effect of heart rate reduction during ischaemia may reflect slower development of ischaemia-induced electrophysiological changes.